Hzymes Biotech has been named a 2026 Bioz Rising Star™ in the Enzymes category. The Bioz Stars Awards recognize suppliers behind scientific progress, drawing on publication-based evidence to celebrate the products researchers use in their work.

Bioz currently lists 19 Hzymes products, with Bioz Stars scores of 92 to 94 out of 100 for the products on its first page of results. Many of them support mRNA research, from in vitro transcription enzymes to enzyme-based capping.

Hzymes products cited in the literature

•       T7 RNA Polymerase: cited in a 2025 study of an mRNA vaccine against Omicron variants derived from the JN.1 spike protein.

•       DNase I and Hi-Yield T7 In Vitro Transcription Reagent (Thermostable): cited in a 2025 bioRxiv preprint on self-circularizing RNA made in cells.

•       Cap1 Capping System: cited in work on an mRNA-based platform targeting staphylococcal enterotoxin B.

•       Vaccinia Virus Capping Enzyme: cited in a 2024 Journal of Translational Medicine study of CAR-NK cells for acute lymphoblastic leukemia.

•       dsRNA ELISA Kit: cited in a 2026 Nucleic Acids Research paper on engineering T7 RNA polymerase for higher stability and activity.

•       T7 RNA Polymerase ELISA Kit: cited in a 2026 Lab on a Chip paper on an automated microfluidic platform for mRNA synthesis and purification.

•       RNase R: cited in a 2025 Microchemical Journal study of microfluidic genotyping of a deafness-linked mitochondrial mutation.

Other Hzymes products listed on Bioz include RNase Inhibitor, BspQI and Recombinant Trypsin Digestion Solution.

We thank the researchers who use and cite our enzymes, and the Bioz team for the recognition. Congratulations also to the other 2026 honorees in the Enzymes category: New England Biolabs, Promega Corporation and R&D Systems.

Learn more about the Bioz Stars Awards and browse Hzymes products on Bioz.